Micafungin Accord

Micafungin, the active ingredient in Micafungin Accord, is an echinocandin presented as an intravenous solution for intravenous use. It is employed to treat invasive candidiasis, esophageal candidiasis, Candida peritonitis and intra‑abdominal infections, and for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

GNH USA supplies Micafungin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets with dedicated logistics support for temperature‑controlled shipments where required.

Micafungin is an echinocandin antifungal that targets invasive Candida infections and related conditions. - Invasive candidiasis: effective treatment to eradicate bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: resolves mucosal infection and alleviates associated pain. - Candida peritonitis and intra‑abdominal infections: clears infection within the abdominal cavity. - Prophylaxis in hematopoietic stem cell transplantation: prevents Candida infection in immunocompromised transplant recipients.

Micafungin may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Fever: transient rise in body temperature occurring during or shortly after the intravenous infusion, often manageable with antipyretics. - Nausea: mild to moderate sensation of queasiness that may accompany treatment, typically resolving without specific therapy. - Elevated liver enzymes: mild increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) detected in routine blood tests, usually reversible after discontinuation.

Serious or Rare Side Effects: - Anaphylaxis: acute, potentially life‑threatening allergic reaction characterized by airway swelling, hypotension, and rash, requiring immediate emergency care. - Hepatic dysfunction: significant elevation of liver enzymes, bilirubin rise, or jaundice indicating liver injury, necessitating treatment interruption and monitoring. - Neutropenia: marked reduction in neutrophil count that can predispose to secondary infections, warranting close hematologic surveillance.

When using Micafungin, clinicians should observe several precautionary measures to ensure patient safety and drug stability. - Liver function monitoring: obtain baseline ALT/AST and bilirubin levels and repeat periodically during therapy. - Renal assessment: evaluate creatinine clearance before initiating treatment, especially in patients with pre‑existing kidney disease. - Hypersensitivity screening: check for prior allergic reactions to echinocandins or related compounds before infusion. - Dose adjustment: consider reduced dosing or increased monitoring in patients with severe hepatic impairment. - Concomitant drug review: assess for potential interactions with agents metabolized by CYP3A4 or those affecting coagulation. - Store at 2‑8 °C: keep the intravenous solution refrigerated, protect from light, and do not freeze or shake the vial.

Micafungin may interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Cyclosporine: co‑administration can increase micafungin plasma concentrations, raising risk of toxicity. - Rifampin: strong enzyme inducer that markedly reduces micafungin exposure, potentially compromising antifungal effectiveness.

Moderate Interactions (Monitor Closely): - Warfarin: micafungin may enhance anticoagulant effect; monitor INR and adjust dose as needed. - Azole antifungals (e.g., fluconazole): combined use may alter hepatic metabolism; observe liver function tests. - Statins (e.g., simvastatin): possible increase in statin levels; assess for signs of myopathy and adjust therapy if required.